102 related articles for article (PubMed ID: 23501241)
1. [Impact of cutaneous toxicities associated with targeted therapies on quality of life. Results of a longitudinal exploratory study].
Charles C; Sultan S; Bungener C; Mateus C; Lanoy E; Dauchy S; Verschoore M; Robert C
Bull Cancer; 2013 Mar; 100(3):213-22. PubMed ID: 23501241
[TBL] [Abstract][Full Text] [Related]
2. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients.
Ra HS; Shin SJ; Kim JH; Lim H; Cho BC; Roh MR
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e53-9. PubMed ID: 22329482
[TBL] [Abstract][Full Text] [Related]
3. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
6. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs.
Rouanne M; Massard C; Hollebecque A; Rousseau V; Varga A; Gazzah A; Neuzillet Y; Lebret T; Soria JC
Eur J Cancer; 2013 Jan; 49(2):431-8. PubMed ID: 22959468
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
10. [Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].
Voilliot-Trotot C; Granel-Brocard F; Geoffrois L; Tréchot P; Nguyen-Thi P; Schmutz JL; Barbaud A
Ann Dermatol Venereol; 2013 May; 140(5):353-62. PubMed ID: 23663707
[TBL] [Abstract][Full Text] [Related]
11. [Management of the cutaneous side effects of chemotherapies and targeted therapies].
Delyon J; Gerard M; Nicodeme M; Fromantin I; Loirat D
Soins; 2015 Jun; (796):17-24. PubMed ID: 26146316
[TBL] [Abstract][Full Text] [Related]
12. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Reactions to Targeted Therapy.
Lee JJ; Kroshinsky D; Hoang MP
Am J Dermatopathol; 2017 Feb; 39(2):67-82. PubMed ID: 28134724
[TBL] [Abstract][Full Text] [Related]
18. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.
Wagner LI; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):34-6. PubMed ID: 18154217
[TBL] [Abstract][Full Text] [Related]
19. Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study.
Charles C; Razavi D; Bungener C; Mateus C; Lanoy E; Verschoore M; Dauchy S; Robert C
Clin Drug Investig; 2016 Mar; 36(3):235-42. PubMed ID: 26754775
[TBL] [Abstract][Full Text] [Related]
20. Effects of socioeconomic factors and cancer survivors' worries on their quality of life (QOL) in Japan.
Kobayashi K; Morita S; Shimonagayoshi M; Kobayashi M; Fujiki Y; Uchida Y; Yamaguchi K
Psychooncology; 2008 Jun; 17(6):606-11. PubMed ID: 17972358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
